PDCD1 and neuropathy: Our key findings included patients self-identifying as “Other” race (Table 1; Odds Ratio (OR) 1.514, 95% CI 1.071–2.140, p = 0.0189) and non-Hispanic or Latino ethnicity (Table 1; OR 1.502, 95% CI 1.113–2.028, p = 0.0078) having higher prevalence of documented neuropathy associated with PD-1 inhibitor exposure, and current-smokers having lower prevalence of documented neuropathy associated with PD-1 inhibitor exposure (Table 1; OR 0.716, 95% CI 0.523–0.980, p = 0.0368).